Cellectis ADR (CLLS)

NASD · Healthcare · Biotechnology · France

Cellectis ADR is a micro cap company (market value under $300 million) in the Biotechnology industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cellectis ADR stock.

Our verdict on CLLS

Not valued: We cannot value this company yet.

We do not publish a value for this company: there is no balance sheet on file to value what it owns.

ETFs with the most weight in CLLS

• iShares Biotechnology ETF (IBB): 0.0% of the fund

Browse

• Stocks in France

Peers in Biotechnology

• Vertex Pharmaceuticals Inc (VRTX)
• Regeneron Pharmaceuticals Inc (REGN)
• Moderna Inc (MRNA)
• Argen X SE ADR (ARGX)
• Revolution Medicines Inc (RVMD)
• Royalty Pharma plc (RPRX)
• BeOne Medicines Ltd ADR (ONC)
• Genmab ADR (GMAB)

All 598 Biotechnology stocks

Cheaper than CLLS in Biotechnology

• Arbutus Biopharma Corp (ABUS): undervalued, 79% margin of safety
• Lakefront Biotherapeutics NV ADR (LKFT): undervalued, 77% margin of safety
• CorMedix Inc (CRMD): undervalued, 74% margin of safety
• MeiraGTx Holdings plc (MGTX): undervalued, 73% margin of safety
• Bicycle Therapeutics Plc ADR (BCYC): undervalued, 71% margin of safety
• Innoviva Inc (INVA): undervalued, 71% margin of safety

134 more in this industry show a wider margin of safety.

Is CLLS undervalued or overvalued?

We do not publish a verdict on CLLS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of CLLS?

We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.